Akèy › Lukemi miyoyid nan faz kwonik
Etid klinik pou Lukemi miyoyid nan faz kwonik ap rekrite nan Etazini
11 etid pou Lukemi miyoyid nan faz kwonik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
- Alabama3 etid
- Georgia3 etid
- Kalifòni5 etid
- New York5 etid
- North Carolina3 etid
- Oregon4 etid
- Texas6 etid
- Washington3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT01746836Study of Olverembatinib (HQP1351) in Patients With CML-CP
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06423911Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT04838041Personalized NK Cell Therapy in CBT
Ap rekriteFaz 2
Laj 15 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT02727803A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Jul 28, 2026 · NCT07020533A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
Ap rekriteEtid obsèvasyon
Laj 18 a 100 · Tout sèks · Mizajou Jul 20, 2026 · NCT07091019Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Ap rekrite
Laj 0 a 25 · Tout sèks · Mizajou May 13, 2026 · NCT05794880A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 1, 2026 · NCT05304377Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 10, 2026 · NCT06229860A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jan 12, 2026 · NCT06163430Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.